Patent · US Active

Delayed release composition for peroral administration

US11654115B2 · kind B2 · utility

3Cited by

1References

23Claims

0Family size

Assignee

VICORE PHARMA AB · SE

Inventors

Ola Camber · Stockholm, SE
Christina JOHANSSON · Stockholm, SE

Key dates

Filing date	Mar 17, 2022
Grant date	May 23, 2023
Priority date	—
Expiry date	Mar 17, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P11/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.